Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance

Haematologica. 2021 Apr 1;106(4):1163-1166. doi: 10.3324/haematol.2020.246843.

Affiliations

¹ Dept. of Experimental Medical Science, Medical Structural Biology, Lund University, Sweden.
² Dept. of Laboratory Medicine, Division of Clinical Genetics, Lund University, Sweden.
³ Department of Pharmacy, University of Pisa, Pisa, Italy.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cytarabine* / therapeutic use
Glucose Transporter Type 1 / genetics
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics

Substances

Antimetabolites, Antineoplastic
Glucose Transporter Type 1
Cytarabine

Grants and funding

Funding: this work was supported by Swedish Research Council (2016-01319 and 2017-05816) and the Swedish Cancer Society (2017/307).